Clinical trials show two more Covid treatments which can potentially save lives and cut hospital time droitwichstandard.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from droitwichstandard.co.uk Daily Mail and Mail on Sunday newspapers.
CORONAVIRUS patients admitted to intensive care units are to get life-saving new treatments which can reduce the time spent in hospital by up to ten days, the Government has announced today. Results from the Government-funded REMAP-CAP clinical trial published today showed tocilizumab and sarilumab reduced the relative risk of death by 24 per cent, when administered to patients within 24 hours of entering intensive care. Most of the data came from when the drugs were administered in addition to a corticosteroid, such as dexamethasone, also discovered through government-backed research through the RECOVERY clinical trial, which is already provided as standard of care to the NHS. Patients receiving these drugs, typically used to treat rheumatoid arthritis, left intensive care between seven to ten days earlier on average.
7 January 2021
Government ensures life-saving drugs will be available in NHS healthcare settings with immediate effect
Patients across the UK who are admitted to intensive care units due to COVID-19 are set to receive new life-saving treatments which can reduce the time spent in hospital by up to 10 days, the government has announced today (Thursday 7 January).
Results from the government-funded REMAP-CAP clinical trial published today showed tocilizumab and sarilumab reduced the relative risk of death by 24%, when administered to patients within 24 hours of entering intensive care.
Most of the data came from when the drugs were administered in addition to a corticosteroid, such as dexamethasone – also discovered through government-backed research through the RECOVERY clinical trial – which is already provided as standard of care to the NHS.
E-Mail
IMAGE: Daniel J. Rubin, MD, MSc, FACE, Associate Professor of Medicine at the Lewis Katz School of Medicine at Temple University, Chair of the Glycemic Control Taskforce at Temple University Hospital. view more
Credit: Temple University Health System
(Philadelphia, PA) - Each year in the United States, more than 1 million patients with diabetes make return trips to the hospital for diabetes-related illness, often being readmitted within 30 days of their initial hospitalization. The costs of these return visits add up, in terms of dollars and in terms of the toll on patient health that comes with prolonged or chronic illness and repeated hospitalization.
Date Time
New project to help tackle Type 1 Diabetes
The Australian National University (ANU) has announced a new research project with Janssen Research & Development, LLC, aimed at improving health outcomes in Type 1 Diabetes (T1D).
The collaboration was facilitated by Johnson & Johnson Innovation.
The project will focus on the development of new methods for measuring and monitoring disease activity.
Type 1 Diabetes is an autoimmune disease that attacks the body’s ability to process sugar by destroying insulin-producing beta cells in the pancreas.
Researchers from ANU will test new methods of monitoring this damage, as part of the wider effort to develop preventive measures and therapies.